Editas Medicine Inc (EDIT) is around the top of the Biotechnology industry according to InvestorsObserver. EDIT received an overall rating of 60, which means that it scores higher than 60 percent of all stocks. Editas Medicine Inc also achieved a score of 77 in the Biotechnology industry, putting it above 77 percent of Biotechnology stocks. Biotechnology is ranked 35 out of the 148 industries.
What do These Ratings Mean?
Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.
These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.
What's Happening With Editas Medicine Inc Stock Today?
Editas Medicine Inc (EDIT) stock is down -4.9% while the S&P 500 has gained 1.11% as of 2:08 PM on Thursday, Sep 24. EDIT is lower by -$1.54 from the previous closing price of $31.45 on volume of 698,750 shares. Over the past year the S&P 500 has risen 9.65% while EDIT has gained 25.99%. EDIT lost -$2.50 per share the over the last 12 months.